NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 261)
Posted On: 11/20/2018 5:14:40 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Raises $1.5M in Private Placement to Fund Canadian Lab
British Columbia, Canada-based Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is a biotechnology company and developer of technology which has demonstrated faster and more effective delivery of cannabinoids and nicotine. Recently, LXRP raised funds through a non-brokered private placement that it intends to use toward the construction of a new Canadian lab, research & development and general corporate purposes. A recent article discussing the company reads, “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has raised, in a non-brokered private placement, a total of $1,515,440. Net proceeds will be used for construction of a new lab in Canada, LXRP-driven R&D and general corporate purposes. The offering consists of 947,150 units at an issue price of $1.60 per unit (http://nnw.fm/g81uD). Lexaria, due to strong demand, increased the size of the placement.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
British Columbia, Canada-based Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is a biotechnology company and developer of technology which has demonstrated faster and more effective delivery of cannabinoids and nicotine. Recently, LXRP raised funds through a non-brokered private placement that it intends to use toward the construction of a new Canadian lab, research & development and general corporate purposes. A recent article discussing the company reads, “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has raised, in a non-brokered private placement, a total of $1,515,440. Net proceeds will be used for construction of a new lab in Canada, LXRP-driven R&D and general corporate purposes. The offering consists of 947,150 units at an issue price of $1.60 per unit (http://nnw.fm/g81uD). Lexaria, due to strong demand, increased the size of the placement.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)